162 related articles for article (PubMed ID: 31487621)
1. Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold.
Li Z; Ren Q; Wang X; Zhou Z; Hu L; Deng L; Guan L; Qiu Q
Bioorg Chem; 2019 Nov; 92():103209. PubMed ID: 31487621
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold.
Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H
Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
Li Z; Wang X; Xu X; Yang J; Xia W; Zhou X; Huang W; Qian H
Bioorg Med Chem; 2015 Nov; 23(22):7158-64. PubMed ID: 26482570
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.
Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z
Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
[TBL] [Abstract][Full Text] [Related]
7. Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Liu C; Xu X; Qiu Q; Su X; Dai Y; Yang J; Li H; Shi W; Liao C; Pan M; Huang W; Qian H
Eur J Med Chem; 2017 Sep; 138():458-479. PubMed ID: 28689096
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
[TBL] [Abstract][Full Text] [Related]
10. Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold.
Li Z; Xu X; Hou J; Wang S; Jiang H; Zhang L
Bioorg Chem; 2018 Apr; 77():429-435. PubMed ID: 29433092
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
Wang X; Zhao T; Yang B; Li Z; Cui J; Dai Y; Qiu Q; Qiang H; Huang W; Qian H
Bioorg Med Chem; 2015 Jan; 23(1):132-40. PubMed ID: 25481394
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of a series of novel phenylpropanoic acid derivatives agonists for the FFA1.
Yang J; Gu E; Yan T; Shen D; Feng B; Tang C
Chem Biol Drug Des; 2019 May; 93(5):900-909. PubMed ID: 30657643
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents.
Ye Z; Liu C; Zou F; Cai Y; Chen B; Zou Y; Mo J; Han T; Huang W; Qiu Q; Qian H
Bioorg Med Chem; 2020 Jul; 28(13):115574. PubMed ID: 32546302
[TBL] [Abstract][Full Text] [Related]
15. A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice.
Li Z; Liu C; Zhou Z; Hu L; Deng L; Ren Q; Qian H
Pharmacol Res; 2020 Mar; 153():104679. PubMed ID: 32014571
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
Li Z; Chen Y; Zhang Y; Jiang H; Liu Y; Chen Y; Zhang L; Qian H
Bioorg Chem; 2018 Oct; 80():296-302. PubMed ID: 29980115
[TBL] [Abstract][Full Text] [Related]
17. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.
Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H
Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358
[TBL] [Abstract][Full Text] [Related]
19. A potent free fatty acid receptor 1 agonist with a glucose-dependent antihyperglycemic effect.
Wang X; Xu Y; Feng S; Huang X; Meng X; Chen J; Guo L; Ge J; Zhang J; Chen J; Cheng L; Gu K; Zhang Y; Jiang Q; Ning X
Chem Commun (Camb); 2019 Aug; 55(61):8975-8978. PubMed ID: 31290492
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
